5 completed, 1 terminated, 1 withdrawn. 4 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Xequel Bio, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of Granexin® Gel to Improve Burn Wound Healing Granexin® gel (200 μM), Vehicle gel - Second Degree Burn, Thermal Burn | Phase 2 | Withdrawn | Xequel Bio, Inc. | 2022-08-01 | 2023-06-22 | |
| Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1), iNexin™ (2.0% aCT1) - Dry Eye Disease | Phase 1 | Completed | Xequel Bio, Inc. | 30 | 2021-09-28 | 2022-03-04 |
| A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery Granexin® gel 100 μM, Granexin® gel 200 μM, Vehicle gel - Mammoplasty, Scarring | Phase 2 / Phase 3 | Completed | Xequel Bio, Inc. | 184 | 2020-07-01 | 2022-06-06 |
| A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer Granexin gel, Vehicle gel - Diabetic Foot Ulcers | Phase 3 | Terminated | Xequel Bio, Inc. | 124 | 2018-11-21 | 2020-05-29 |
| Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers Granexin - Venous Leg Ulcer | Phase 1 | Completed | Xequel Bio, Inc. | 10 | 2015-09-01 | 2018-08-01 |
| Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers Granexin® gel - Diabetic Foot Ulcers | Phase 1 | Completed | Xequel Bio, Inc. | 16 | 2015-09-01 | 2018-08-01 |
| Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy FSR Peptide 20μM, FSR Peptide 50μM, FSR Peptide 100μM - Wound Heal | Phase 1 | Completed | Xequel Bio, Inc. | 49 | 2008-03-06 | 2020-07-20 |
Diabetic Foot (2) · Cicatrix (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Dry Eye Syndromes (1) · Varicose Ulcer (1)
United States (5) · Canada (1) · Hungary (1) · India (1) · Poland (1) · Switzerland (1)
Gautam Ghatnekar (1)